A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled,
oral single and multiple ascending-doses, parallel group study to evaluate the safety,
tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1
clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD])
and Part B (multiple ascending dose [MAD]).